TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,050,000 | -41.4% | 7,500,000 | +0.7% | 1.03% | -38.0% |
| Q2 2023 | $114,432,000 | -28.8% | 7,450,000 | +4.2% | 1.66% | -28.5% |
| Q1 2023 | $160,758,520 | +19.2% | 7,148,000 | +11.5% | 2.32% | -1.6% |
| Q4 2022 | $134,844,360 | -6.2% | 6,412,000 | +9.9% | 2.35% | -5.7% |
| Q3 2022 | $143,799,000 | +11.6% | 5,836,000 | +9.7% | 2.49% | +10.9% |
| Q2 2022 | $128,904,000 | +0.9% | 5,320,000 | +7.3% | 2.25% | -9.0% |
| Q1 2022 | $127,768,000 | +0.9% | 4,958,000 | +21.6% | 2.47% | +19.3% |
| Q4 2021 | $126,581,000 | +9.9% | 4,078,000 | -14.1% | 2.07% | +6.3% |
| Q3 2021 | $115,139,000 | +37.3% | 4,748,000 | -17.4% | 1.95% | +29.9% |
| Q2 2021 | $83,863,000 | +42.6% | 5,748,000 | +144.0% | 1.50% | +11.1% |
| Q1 2021 | $58,829,000 | – | 2,356,000 | – | 1.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |